Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double Blind, Parallel-group, Placebo Controlled Study to Evaluate the Efficacy and Safety of IBP-9414 in Premature Infants 500-1500g Birth Weight in the Prevention of Necrotizing Enterocolitis - The Connection Study

Trial Profile

A Randomized, Double Blind, Parallel-group, Placebo Controlled Study to Evaluate the Efficacy and Safety of IBP-9414 in Premature Infants 500-1500g Birth Weight in the Prevention of Necrotizing Enterocolitis - The Connection Study

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 06 Mar 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Limosilactobacillus reuteri (Primary) ; Limosilactobacillus reuteri (Primary)
  • Indications Acute enterocolitis
  • Focus Registrational; Therapeutic Use
  • Acronyms Connection
  • Sponsors Infant Bacterial Therapeutics
  • Most Recent Events

    • 21 Jun 2023 According to an Infant Bacterial Therapeutics media release, company have thus far enrolled more than 1,650 of the planned 2,158 premature babies.
    • 21 Jun 2023 According to an Infant Bacterial Therapeutics media release, trial received approval from Data Monitoring Committee (DMC) and recruitment can continue as planned with the approved study protocol. DMC has performed a pre-planned futility safety analysis of data of 1403 babies. The information was submitted for publication, through the agency of the contact persons set out above, at 17:20 CET on June 21, 2023.
    • 15 Jun 2023 According to an Infant Bacterial Therapeutics media release, the company announced that the European Patent Office has approved its patent application for Lactobacillus reuteri.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top